Welcome to our dedicated page for Takeda Pharm news (Ticker: TAK), a resource for investors and traders seeking the latest updates and insights on Takeda Pharm stock.
Takeda Pharmaceutical Company Limited (TAK) maintains its position as a global biopharmaceutical leader through continuous innovation in oncology, gastroenterology, and rare disease therapies. This news hub provides investors and healthcare professionals with essential updates on Takeda's operational developments and strategic direction.
Access consolidated information on quarterly earnings, regulatory milestones, and research breakthroughs across Takeda's core therapeutic areas. Our curated news collection simplifies tracking of partnership announcements, clinical trial results, and market expansion initiatives that shape the company's growth trajectory.
Key updates include developments in plasma-derived therapies, neuroscience advancements, and global health initiatives. The resource serves as a centralized platform for monitoring how Takeda's $4B+ annual R&D investment translates into therapeutic innovations and market leadership.
Bookmark this page for real-time updates on Takeda's progress in addressing complex medical needs through science-driven solutions. Stay informed about critical updates affecting one of Japan's most influential pharmaceutical enterprises and its global healthcare impact.
Protagonist Therapeutics (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announced positive topline results from their Phase 3 VERIFY study of rusfertide in polycythemia vera (PV) patients. The study achieved its primary endpoint with 77% of rusfertide-treated patients showing clinical response compared to 33% in the placebo group.
The trial met all four key secondary endpoints, including the EU primary endpoint showing 0.5 phlebotomies per patient in the rusfertide arm versus 1.8 in the placebo arm. Rusfertide, a first-in-class hepcidin mimetic peptide therapeutic with FDA Orphan Drug and Fast Track designations, demonstrated favorable safety with mainly grade 1-2 injection site reactions.
Following these positive results, Protagonist will receive a $25 million milestone payment from Takeda upon completion of the VERIFY clinical study report.
Takeda (NYSE: TAK) has received EMA approval for an additional subcutaneous administration option of TAKHZYRO® (lanadelumab) for HAE patients aged 12 years and above. The new 2 mL pre-filled pen joins existing delivery options including 150 mg and 300 mg pre-filled syringes and 300 mg vials.
The approval expands treatment options for Hereditary Angioedema (HAE), a rare condition affecting approximately 1 in 50,000 people worldwide. TAKHZYRO is approved in the EU for routine prevention of recurrent HAE attacks in patients aged 2 years and older. The new pre-filled pen contains 300 mg of lanadelumab in 2 mL solution, with approval supported by clinical study data.
Takeda (TOKYO:4502/NYSE:TAK) has announced that Julie Kim, current president of Takeda's U.S. Business Unit, will succeed Christophe Weber as CEO when he retires in June 2026. The decision was made unanimously by the Board of Directors after a multi-year succession process evaluating both internal and external candidates.
Weber, who joined Takeda in 2014 and became CEO in 2015, has led the company's transformation into a global R&D-driven biopharmaceutical company. The timing of this succession aligns with Takeda's competitive growth outlook and new product launches expected from the second half of 2026.
Kim, who has been with Takeda's Executive Team since 2019 and leads the U.S. Business Unit since 2022, brings three decades of healthcare experience across various leadership positions. She will be proposed as a candidate for Board election at Takeda's Annual General Shareholders Meeting in June 2026.
Takeda reported strong Q3 FY2024 results with revenue growth of 9.8% at actual exchange rates and 4.5% at constant exchange rate. Growth & Launch Products showed impressive momentum with 14.6% growth at CER. Core Operating Profit increased by 10.1% at CER, with margin reaching 28.5%.
The company has raised its full-year outlook, increasing its Adjusted Free Cash Flow forecast by JPY 150.0 billion to JPY550.0-650.0 billion. Takeda announced a share buyback program of up to JPY 100.0 billion, demonstrating confidence in business momentum.
The pipeline shows strong progress with three Phase 3 data readouts expected in 2025, and eight regulatory filings planned between FY2025-FY2029. Six late-stage programs have potential peak revenues of USD 10-20 billion in total.
Takeda (TSE:4502/NYSE:TAK) has received approval from Japan's Ministry of Health for HYQVIA®, the first facilitated subcutaneous immunoglobulin (fSCIG) therapy for patients with agammaglobulinemia or hypogammaglobulinemia. The treatment combines Immunoglobulin 10% with Recombinant Human Hyaluronidase PH20, allowing larger volume infusions and reduced dosing frequency to once every 3-4 weeks versus weekly/bi-weekly with conventional treatments.
The approval is based on two Phase 3 studies in Japan involving 16 patients aged 2+ years, showing maintained IgG trough levels of 9.494g/L. Main adverse reactions included pyrexia (31.3%) and various infusion site reactions (12.5%). The approval expands Takeda's immunoglobulin therapy portfolio in Japan.
Takeda showcases its late-stage pipeline featuring six programs with potential peak revenue of $10B-$20B. The company expects Phase 3 data readouts in 2025 for three key treatments: oveporexton (narcolepsy), zasocitinib (psoriasis), and rusfertide (polycythemia vera), with regulatory filings planned for FY2025-2026.
The pipeline includes additional promising treatments: mezagitamab for immune disorders, fazirsiran for liver disease, and elritercept for anemia in hematologic cancers. Five more regulatory filings are anticipated during FY2027-2029, demonstrating Takeda's commitment to sustainable growth through 2030 and beyond.
Takeda has entered into an exclusive licensing agreement with Keros Therapeutics for elritercept, a late-stage activin inhibitor designed to treat anemia in hematologic cancers. The agreement grants Takeda exclusive global rights outside mainland China, Hong Kong, and Macau. Elritercept targets myelodysplastic syndromes (MDS) and myelofibrosis (MF), and has received FDA Fast Track designation for MDS treatment. The drug has shown promising clinical activity in early studies. Takeda will pay $200 million upfront, plus potential milestone payments and royalties. Two Phase 2 trials are ongoing, with a Phase 3 RENEW trial for MDS patients starting soon.
Alloy Therapeutics and Takeda have announced a strategic collaboration and license agreement to develop Takeda's proprietary induced pluripotent stem cell (iPSC) derived CAR-T cell platform (iCAR-T) and iPSC-derived CAR-NK platform (iCAR-NK). The technology, developed through Takeda's T-CiRA joint research program with Kyoto University, aims to create 'off-the-shelf' cell therapies with enhanced potency and lower manufacturing costs compared to autologous cell therapy. Under the agreement, Alloy gains co-exclusive rights to commercialize iCAR-T and iCAR-NK products for oncology indications. Alloy will establish a Japanese subsidiary at Shonan Health Innovation Park to support these efforts.
Takeda reported strong H1 FY2024 results with revenue growth of +13.4% (AER) and +5.0% (CER), driven by Growth & Launch Products (+18.7% CER). Core Operating Profit increased by +12.9% CER with a margin of 30.2%. The company upgraded its FY2024 outlook due to stronger performance and milder VYVANSE generic erosion. Notable achievements include ENTYVIO's double-digit growth, ADZYNMA's EU approval, FRUZAQLA's Japan launch, and TAK-861's Phase 3 trial initiation for narcolepsy. The revised guidance projects flat to slightly increasing core revenue, with core operating profit showing a mid-single-digit decline.
Takeda and Boston Medical Center (BMC) announced a three-year collaboration to reduce greenhouse gas emissions in healthcare, focusing on regulated medical waste and pharmaceutical packaging. The initiative aims to identify and pilot decarbonization solutions that can be shared across the healthcare ecosystem. BMC will conduct waste audits in clinical areas to identify emission hotspots and test new technologies. This partnership supports Takeda's goal to achieve net-zero emissions in operations by 2035 and across its value chain by 2040, recently validated by the Science Based Targets initiative.
